Navigation Links
Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 8th Annual BIO Investor Forum. The presentation is scheduled for 2:30 p.m. PDT on Thursday, October 29, at the Palace Hotel in San Francisco, Calif. The BIO Investor Form gives investors the opportunity to hear from and meet with executives from top life sciences growth companies.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.

SOURCE Amira Pharmaceuticals, Inc.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
2. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
4. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
5. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
6. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
7. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
8. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
9. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
10. Amira Pharmaceuticals Appoints First Vice President of Development
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... David Kekich, anti-aging icon and CEO of ... that the acceptance of his revolutionary approach of ... algorithms and then screening thousands of compounds against ... , “It took longer than I thought and ... said Kekich. "Client acceptance is exploding, early clinical ...
(Date:7/31/2014)... Malaysia (PRWEB) July 31, 2014 ... mymobileuni.com, entered into strategic alliance with Dr. Lawrence ... and provide content to http://www.mymobileuni.com its ... Channel http://www.mymobileuni.net/mu3/health.php will include courses, e-books ... who want to learn, re-skill or up-skill themselves ...
(Date:7/31/2014)... 2014 (HealthDay News) -- The virus that causes cold sores ... the absence of symptoms, according to a new study. ... the cells of people infected with the virus. This explains ... and why others get them only occasionally. The authors said ... "We thought when the disease was dormant, it ...
(Date:7/31/2014)... MO (PRWEB) July 31, 2014 Saint ... with an Excellence Through Insight award for Overall Patient ... and Systems (CG-CAHPS) database in multiple categories by HealthStream, ... their commitment to excellence in patient care. To qualify ... been a patient satisfaction-tracking client of HealthStream in 2013, ...
(Date:7/31/2014)... OK (PRWEB) July 31, 2014 Shiitakes ... As in the recipe for Quick-Fix Spaghetti Sauce below, ... second-most consumed mushroom worldwide, valued for their deep flavor ... mushrooms. They absorb flavors of the foods they're cooked ... texture and offer high-protein, low-fat nutrition. Shiitakes are rich ...
Breaking Medicine News(10 mins):Health News:MaxLife Solution™ Expands Distribution Globally for Breakthrough Anti-Inflammatory Support Supplement – InflaGene™ 2Health News:MyMobileUniversity and Fortech International Form Strategic Alliance That Will Enhance the Global Health and Medical Channel on Its Website 2Health News:Cold Sore Virus Active Without Symptoms, Study Finds 2Health News:Saint Luke’s Health System Physicians and Clinics Earn Excellence through Insight Awards for Overall Patient Experience in the CG-CAHPS Database 2Health News:Saint Luke’s Health System Physicians and Clinics Earn Excellence through Insight Awards for Overall Patient Experience in the CG-CAHPS Database 3Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 2Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 3
... encouraging results for the long-term efficacy of a meningitis ... effective when given to infants older than 5 months.// ... the United Kingdom in 1999. While the short-term effectiveness ... a study looking at the data from the four ...
... risk of developing dementia later in life, a healthy diet ... conducted, researchers followed nearly 1,500 participants for more than 20 ... were twice as likely to develop dementia later in life. ... in middle age were six-times more likely to develop dementia ...
... suggests that older patients can avoid the risk of stroke by ... who ate fish; one to four// times a week had ... atrial fibrillation), than those who ate fish less than once a ... greater benefit – as their risk was lowered by 31%. However ...
... on active baby boomers. Arthritis followed by knee replacement surgery ... middle-aged Americans. Now a new technique offers hope for active ... feet, crouching and clicking, kneeling and directing. His glamour photography ... lifeblood," he says. "If they don't work, I don't work." ...
... it safe for people with heart disease to travel by ... on // issues involving air travel for heart patients -- ... on implantable automatic defibrillators and pacemakers, the need for preflight ... dangerous blood clot that can arise in the leg when ...
... heart attack patients fare better after having a procedure to ... results // from a recent study. The study, conducted in ... a group of about 870 men and about 160 women ... heart attack. While both sexes had about the same success ...
Cached Medicine News:
(Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
(Date:7/31/2014)... , July 31, 2014 Hovione today ... has successfully passed a pre-approval inspection by the ... carried out by the FDA Consumer Safety Officer, Ms. ... on 21 st July and concluded on the 25 ... with the principles and guidelines of Good Manufacturing Practices (GMP) ...
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
Breaking Medicine Technology:Touro University California Garners Grant From Long Foundation 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... MVP Marketing + Design, Inc., a Minneapolis-based, branding, communications ... of eleven American Graphic Design Awards for selected client ... online and retail promotions created for three separate divisions ... (Skin and Wound Care, Office Supplies and Stationery Products), ...
... announces the approval of CollaGUARD surgical adhesion barrier for ... surgery. The product will be launched this year through ... to seek approval in a number of additional territories, ... and to initiate the studies required for registration in ...
Cached Medicine Technology:MVP Sweeps 2011 American Graphic Design Awards with Nine of 11 Wins for 3M Projects 2Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier 2Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier 3
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Colorimetric Assay of Plasminogen Activity by STA© Analyzers....
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
Calibration Plasmas for Assaysof Unfractionated Heparins (UFH) using the Anti-Xa Method on STA© Analyzers....
Medicine Products: